IDSA offers policy Rx for influenza vaccine shortage

October 21, 2004

In the midst of the current national shortage of influenza vaccine, the Infectious Diseases Society of America (IDSA) today renewed its call for Congress and the Administration to implement innovative public policy geared toward removing financial disincentives that have caused pharmaceutical companies to leave the vaccine market.

"Infectious disease physicians in hospitals and communities across America are grappling with thorny questions about how to ration this year's vaccine among patients who are at highest risk for complications of flu," said Walter E. Stamm, MD, IDSA president. "We are dealing with the consequences for the short term, but we need to think about innovative, long-term policy solutions."

One possible vehicle for addressing the problem is legislation commonly called "Bioshield II," which would build on "The Project Bioshield Act," (Bioshield I), which was signed into law in July 2004. Bioshield I is intended to stimulate the development of treatments, preventatives, and diagnostics related to bioterrorism preparedness and response. IDSA has consistently urged Congress to extend the scope of both Bioshield I and II beyond bioterrorism to include research and development of vaccines and antibiotics to prevent and treat naturally occurring infections.

"Whether we're talking about vaccines to prevent diseases such as the flu or antibiotics to treat drug-resistant infections, the infectious diseases market is simply not as attractive to manufacturers as is the market for chronic diseases, like diabetes or high cholesterol, where patients take a drug for life," said Andrew T. Pavia, MD, chief of the division of pediatric infectious diseases at the University of Utah and chair of IDSA's Pandemic Influenza Task Force.

As compared with a blockbuster drug, many vaccines are used only once or twice in a person's lifetime, or once a year in the case of influenza. But even though the infectious diseases market is relatively small compared to other fields of medicine, the public health need is great. Every year in the United States, influenza causes approximately 36,000 deaths and 200,000 hospitalizations. Despite this critical need, pharmaceutical companies have pulled out of influenza vaccine production because it is financially risky and less profitable than other markets.

Because the flu virus changes from year to year, a new vaccine must be created each flu season. This is a difficult and time-consuming process. The demand for flu shots fluctuates from year to year as public interest waxes and wanes. Last influenza season, for example, 87 million doses of vaccine were made, but only 83 million doses were used. In recent flu seasons, as many as 13 million doses have gone unused and have had to be discarded. Given the challenges, many experts say it is not surprising that so few manufacturers see the market as viable. In the 1970s, there were several pharmaceutical companies producing flu vaccine for the United States. Now there are only two.

"It makes sense for the country to reinvest in the infectious diseases market," said Dr. Pavia. "Vaccines and antibiotics will help to save lives and should be cost-effective for society in the long run. Money we put into incentives should be returned by savings from decreased disease," he said.

"This is why IDSA has been urging federal policymakers to create new incentives--such as tax credits, strengthened intellectual property rights, liability protections, or some type of federally guaranteed purchase program--to make the infectious diseases market more attractive to industry," said John G. Bartlett, MD, chief of the division of infectious diseases at the Johns Hopkins University School of Medicine and chair of IDSA's Task Force on Antimicrobial Availability. Other ideas for making the market more attractive may be worth exploring, he added.

In July, IDSA published a major report, Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates ... A Public Health Crisis Brews, which outlined possible incentives to spur development of new antibiotics. IDSA believes that many of these incentives could also make the vaccine market more attractive to pharmaceutical companies, and that Bioshield II offers a means for putting policy into action.

"Vaccines and antibiotics have been among our chief tools for preventing and treating infectious diseases," said Dr. Stamm. "How can we as infectious disease physicians tell our patients that our tool box is empty? Market forces alone are not going to solve this problem. We need innovative federal policy to protect public health."
-end-
IDSA is an organization of physicians, scientists, and other health care professionals dedicated to promoting human health through excellence in infectious diseases research, education, prevention, and patient care. The Society, which has nearly 7,800 members, was founded in 1963 and is headquartered in Alexandria, Va. For more information, visit www.idsociety.org.

IDSA's Bad Bugs, No Drugs report is available on the Society's website at www.idsociety.org/badbugsnodrugs.

Infectious Diseases Society of America

Related Antibiotics Articles from Brightsurf:

Insights in the search for new antibiotics
A collaborative research team from the University of Oklahoma, the Memorial Sloan Kettering Cancer Center and Merck & Co. published an opinion article in the journal, Nature Chemical Biology, that addresses the gap in the discovery of new antibiotics.

New tricks for old antibiotics
The study published in the journal Immunity reveals that tetracyclines (broad spectre antibiotics), by partially inhibiting cell mitochondria activity, induce a compensatory response on the organism that decreases tissue damage caused during infection.

Benefits, risks seen with antibiotics-first for appendicitis
Antibiotics are a good choice for some patients with appendicitis but not all, according to study results published today in the New England Journal of Medicine.

How antibiotics interact
Understanding bottleneck effects in the translation of bacterial proteins can lead to a more effective combination of antibiotics / study in 'Nature Communications'

Are antivitamins the new antibiotics?
Antibiotics are among the most important discoveries of modern medicine and have saved millions of lives since the discovery of penicillin almost 100 years ago.

Hygiene reduces the need for antibiotics by up to 30%
A new paper published in the American Journal of Infection Control (AJIC), finds improved everyday hygiene practices, such as hand-washing, reduces the risk of common infections by up to 50%, reducing the need for antibiotics, by up to 30%.

Antibiotics: City dwellers and children take the most
City dwellers take more antibiotics than people in rural areas; children and the elderly use them more often than middle-aged people; the use of antibiotics decreases as education increases, but only in rich countries: These are three of the more striking trends identified by researchers of the NRW Forschungskolleg ''One Health and Urban Transformation'' at the University of Bonn.

Metals could be the link to new antibiotics
Compounds containing metals could hold the key to the next generation of antibiotics to combat the growing threat of global antibiotic resistance.

Antibiotics from the sea
The team led by Prof. Christian Jogler of Friedrich Schiller University, Jena, has succeeded in cultivating several dozen marine bacteria in the laboratory -- bacteria that had previously been paid little attention.

Antibiotics not necessary for most toothaches, according to new ADA guideline
The American Dental Association (ADA) announced today a new guideline indicating that in most cases, antibiotics are not recommended for toothaches.

Read More: Antibiotics News and Antibiotics Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.